Paul Tudor Jones’s Janux Therapeutics JANX Stock Holding History

Paul Tudor Jones’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$431K	Sell	28,070 -1,619	-5%	-$23.5K	﹤0.01%	2927
2026 Q1	$413K	Sell	29,689 -49,469	-62%	-$678K	﹤0.01%	2947
2025 Q4	$1.09M	Sell	79,158 -19,398	-20%	-$456K	﹤0.01%	2204
2025 Q3	$2.41M	Sell	98,556 -15,193	-13%	-$370K	﹤0.01%	1681
2025 Q2	$2.63M	Sell	113,749 -60,601	-35%	-$1.6M	0.01%	1479
2025 Q1	$4.71M	Buy	+174,350	New	+$6.57M	0.02%	813
2024 Q3	–	Sell	-67,487	Closed	-$2.83M	–	2915
2024 Q2	$2.83M	Buy	67,487 +61,072	+952%	+$2.87M	0.01%	885
2024 Q1	$242K	Buy	+6,415	New	+$140K	﹤0.01%	1948

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Paul Tudor Jones's JANX Position: Q2 2026 in Review

Paul Tudor Jones reduced its Janux Therapeutics (JANX) stake by 5.5% in Q2 2026, selling an estimated $23.5K and leaving 28,070 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #2927.

Paul Tudor Jones first reported a position in JANX in Q1 2024 and has held it in 8 quarters since. The position peaked at $4.71M in Q1 2025. 196 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Paul Tudor Jones held 28,070 shares of Janux Therapeutics worth $431K as of Q2 2026.
Paul Tudor Jones sold 1,619 Janux Therapeutics shares in Q2 2026, an estimated $23.5K.
Janux Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2927 holding.
Paul Tudor Jones first reported a position in Janux Therapeutics in Q1 2024 and has held it in 8 quarters since.
Paul Tudor Jones's Janux Therapeutics position peaked at $4.71M in Q1 2025.
196 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.